Bayer Stock Breaks Above Key Average as FDA Nod and Supreme Court Verdict Set the Stage for a Hectic Summer

Bayer's shares clear key technical level amid FDA/EMA approvals for Ambelvist and asundexian, but €32.5B debt and pending glyphosate ruling keep risk high.

Bayer’s share price finally cleared the 50?day moving average on Friday, settling at €37.81 after a 2.13% gain — a technical milestone that offers short?term relief for a stock that has spent much of the year wrestling with legal uncertainty and a deteriorating financial backdrop. The breakout, however thin, arrives at a moment when the company’s pipeline is showing unexpected vitality and the judicial calendar is about to deliver what could be the most consequential ruling in its long Roundup saga.

Two regulatory approvals within the space of a week have given the pharma division a much?needed public?relations boost. The FDA granted marketing authorisation on June 15 for Ambelvist (gadoquatrane), a macrocyclic gadolinium?based MRI contrast agent that contains 60?% less gadolinium than conventional products of its class and 20?% less than the next closest competitor, Gadopiclenol. The approval rests on two randomised Phase?III trials covering central nervous system pathologies and diseases outside the nervous system. Just five days earlier, the European Medicines Agency validated Bayer’s marketing application for asundexian, an oral Factor?XIa inhibitor designed to prevent ischaemic stroke in adults who have suffered a non?cardioembolic stroke or a high?risk transient ischaemic attack. The submission represents the first such application in Europe for this drug class, and both the FDA and China’s National Medical Products Administration have already granted priority review, giving Bayer a shot at simultaneous launches in three major markets.

Asundexian is more than a pipeline candidate — it is the designated successor to Xarelto, whose patent cliff has already taken a heavy toll. Sales of the anticoagulant tumbled by a third in 2025 to US?$2.6?billion, leaving a gaping hole in Bayer’s revenue base. Stroke is the second?leading cause of death in Europe, with roughly ten million people living with its aftermath, and the repositioning of asundexian after a 2023 setback in atrial fibrillation patients puts it squarely in a large and underserved market.

The encouraging regulatory news, however, must be weighed against a balance sheet that is groaning under the weight of litigation. In the first quarter of 2026 alone, settlement payments — mostly related to PCB and glyphosate lawsuits — drained roughly €2?billion from the company, pushing net debt to €32.5?billion by the end of March. The next legal milestone is imminent: the US Supreme Court is expected to issue its opinion in the glyphosate pre?emption case known as Durnell before the end of June. A ruling in Bayer’s favour could seal federal law’s primacy over state?level warning claims and remove a major source of future liability, while an adverse outcome would keep the litigation floodgates open and put fresh pressure on the stock.

The court’s decision is just one of three dates that will shape the coming months. On July?9, a final hearing is scheduled in Missouri over a proposed multibillion?dollar settlement framework. Then, in September, a US hearing will weigh potential retaliatory tariffs stemming from German healthcare reforms that Washington argues unfairly constrain pricing for innovative medicines. The trade?related risk adds another layer of unpredictability to an already volatile picture.

Analysts remain divided over the outlook. UBS has a Buy rating with a €52 price target, while Jefferies holds at “Hold” with a €40 target. The wide gap reflects the binary nature of the legal outcomes and the difficulty of modelling a company that must simultaneously manage a €5?billion?plus annual cash drain from settlements, a €32.5?billion debt pile, and the operational transition away from Xarelto.

Bayer is also pursuing cost?cutting initiatives. A newly awarded industry prize for its AI?driven production plant in Leverkusen underscores the company’s efforts to improve manufacturing efficiency. Management expects production costs to fall by 8?% to 12?%, translating into an additional gross profit of €800?million to €1.2?billion over the next five years, with returns on capital well above the sector average. Yet even those savings will barely dent the scale of the legal obligations.

For now, the stock sits at its 50?day moving average, up roughly 41?% on a year?to?date basis but essentially flat compared with this time last year. The 52?week high of nearly €50 remains the aspirational target, but whether Bayer can reach it depends on a Supreme Court opinion that could land any day — and on whether the pipeline’s recent wins translate into genuine commercial traction before the next wave of legal costs arrives.